Shire's Gaucher drug has edge over rival in trial

LONDON Thu Jun 28, 2012 4:04pm IST

Related Topics

Stocks

   

LONDON (Reuters) - Shire's Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi's Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.

The findings from the Shire-sponsored study, made public at a European Working Group on Gaucher Disease in Paris, may help Shire differentiate its product from Cerezyme, which is made by Sanofi's Genzyme unit.

Gaucher disease is a rare genetic disorder affecting some 10,000 patients worldwide. Patients with the disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

For many years Genzyme dominated the Gaucher market with its drug Cerezyme, at one point the most expensive drug in the world costing more than $200,000 a year.

But competition is now increasing. In addition to Vpriv, there is also another Gaucher drug called Elelyso from Protalix Biotherapeutics and Pfizer, which was approved by U.S. regulators in May but was rebuffed in Europe last week.

Ari Zimran of the Hebrew University and Hadassah Medical School, Jerusalem, said the study results showed Vpriv was effective in treating key markers of Gaucher-related bone disease.

Clinically and statistically significant improvements in bone measurements were seen at nine months of treatment with Vpriv but not with Cerezyme.

(Reporting by Ben Hirschler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

HEALTH SHOWCASE

Breast Cancer Fight

Breast Cancer Fight

Roche, Merck extend immunotherapy fight to breast cancer  Full Article 

Office Perks

Office Perks

Apple, Facebook will pay for female employees to freeze their eggs.  Full Article 

It's In The Genes

It's In The Genes

Genetic link to Danish happiness, says study.  Video 

Smoking Effects

Smoking Effects

Americans have 14 million smoking-related ailments: study.  Full Article 

Health Food

Health Food

Olive oil, nuts may help reverse heart risk factors.  Full Article 

Digital Doctors

Digital Doctors

China sees tech cure for healthcare woes.  Full Article 

Stem Cell Study

Stem Cell Study

Stem cells from human embryos prove safe, improve vision - study.  Full Article 

Shortages Impact

Shortages Impact

Shortages hinder Venezuela's battle against fever outbreaks  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage